Double trouble: Therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis

Archives of Dermatology

Volumn 147, Issue 7, 2011, Pages 831-835

  Kim, Nikki N ^a   Lio, Peter A ^a   Morgan, Gabrielle A ^b   Jarvis, James N ^c   Pachman, Lauren M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN S MEMORIAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE DIPROPIONATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; HYDROCORTISONE; METHOTREXATE; METHYLPREDNISOLONE; MOMETASONE FUROATE; MUCIN; MUSCLE ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ARTHRITIS; ARTICLE; CASE REPORT; CHILD; DERMATOMYOSITIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; ENZYME BLOOD LEVEL; ERYTHEMA; FAMILY HISTORY; FATIGUE; FEMALE; GOTTRON PAPULE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE DERMATOMYOSITIS; LOW DRUG DOSE; MUSCLE WEAKNESS; PAPULE; PERIORBITAL EDEMA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; RASH; SKIN BIOPSY; SKIN DEFECT; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DERMATOLOGIC AGENTS; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PHOTOTHERAPY; PREDNISONE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955505027     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.49     Document Type: Article

References (56)

1. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631): 2201-2212. (Pubitemid 351890413)
2. Mendez EP, Lipton R, Ramsey-Goldman R, et al; NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300-305.
3. Dourmishev L, Meffert H, Piazena H. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed. 2004;20(5):230-234. (Pubitemid 39359335)
4. Mamyrova G, O'Hanlon TP, Monroe JB, et al; Childhood Myositis Heterogeneity Collaborative Study Group. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 2006;54(12):3979-3987. (Pubitemid 44955902)
5. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1*0501+children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol. 2002;168(8):4154-4163. (Pubitemid 34298424)
6. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1-2):59-68. (Pubitemid 46786834)
7. Pachman LM, Lipton R, Ramsey-Goldman R, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005;53(2):166-172. (Pubitemid 40530155)
8. Koch MJ, Brody JA, Gillespie MM. Childhood polymyositis: a case-control study. Am J Epidemiol. 1976;104(6):627-631.
9. Massa M, Costouros N, Mazzoli F, et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 2002;46(11): 3015-3025. (Pubitemid 35315896)
10. Vegosen LJ, Weinberg CR, O'Hanlon TP, Targoff IN, Miller FW, Rider LG. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum. 2007;56(8):2719-2728. (Pubitemid 47237291)
11. Cooper GS, Miller FW, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect. 1999; 107(suppl 5):693-700. (Pubitemid 29527772)
12. Wedderburn LR, McHugh NJ, Chinoy H, et al; Juvenile Dermatomyositis Research Group ( JDRG). HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007;46(12):1786-1791. (Pubitemid 350176276)
13. Tomono N, Mori M, Nakajima S, et al. HLA-DRB1*15021 is the predominant allele in Japanese patients with juvenile dermatomyositis. J Rheumatol. 2004; 31(9):1847-1850. (Pubitemid 39202532)
14. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009; 60(6):1815-1824.
15. Chen Y-W, Shi R, Geraci N, Shrestha S, Gordish-Dressman H, Pachman LM. Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol. 2008;9:43.
16. Shrestha S, Wershil B, Sarwark JF, Niewold TB, Philipp T, Pachman LM. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 2010;62(9):2813-2822.
17. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNF-α-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000; 43(10):2368-2377.
18. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord. 1999;9(4):239-246. (Pubitemid 29287259)
19. Fedczyna TO, Lutz J, Pachman LM. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. Clin Immunol. 2001;100:236-239.
20. Uzel G, Pachman LM. Cytokines in juvenile dermatomyositis pathophysiology: potential and challenge. Curr Opin Rheumatol. 2003;15(6):691-697. (Pubitemid 38156294)
21. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2): 136-139. (Pubitemid 38457271)
22. Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17(3):174-178. (Pubitemid 30436592)
23. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866-873.
24. Yao Y, Richman L, Morehouse C, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS One. 2008;3(7):e2737.
25. Farkas A, Tonel G, Nestle FO. Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol. 2008; 158(5):921-929. (Pubitemid 351521462)
26. Niewold T, Wu S, Smith M, Morgan GA, Pachman LM. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics. In Press.
27. Pavlović MD, Zecević RD, Zolotarevski L. Psoriasis in a patientwith dermatomyositis. Vojnosanit Pregl. 2004;61(5):557-559.
28. Alekberova ZS, Balabanova RM, Agababov SV. Dermatomyositis associated with psoriasis [in Russian]. Ter Arkh. 1980;52(4):116-119.
29. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
30. Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 2004;31(8):1644-1649. (Pubitemid 39006649)
31. Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;58:571-576. (Pubitemid 351294893)
32. Lovell DJ, Lindsley CB, Rennebohm RM, et al; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies, II: the Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum. 1999;42(10):2213-2219. (Pubitemid 30263608)
33. Delgado-Vega AM, Alarcón-Riquelme ME, Kozyrev SV. Genetic associations in type I interferon related pathways with autoimmunity. Arthritis Res Ther. 2010; 12(suppl 1):S2.
34. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "type 1" inflammatory gene expression. Trends Immunol. 2004;25(6):295-305. (Pubitemid 38610353)
35. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135-143. (Pubitemid 41002916)
36. Leman J, Burden D. Psoriasis in children: a guide to its diagnosis and management. Paediatr Drugs. 2001;3(9):673-680. (Pubitemid 32996112)
37. Reed AM, Lopez M. Juvenile dermatomyositis: recognition and treatment. Paediatr Drugs. 2002;4(5):315-321. (Pubitemid 34553582)
38. Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol. 2003; 49(2)(suppl):S78-S86. (Pubitemid 36951251)
39. Jury CS, McHenry P, Burden AD. Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol. 2006;31(2):196-199.
40. Ersoy-Evans S, Altaykan A, Sahin S, Kölemen F. Phototherapy in childhood. Pediatr Dermatol. 2008;25(6):599-605.
41. Jain VK, Aggarwal K, Jain K, Bansal A. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol. 2007;46(3):320-322. (Pubitemid 46390297)
42. al-Fouzan AS, Nanda A. A survey of childhood psoriasis in Kuwait. Pediatr Dermatol. 1994;11(2):116-119.
43. Victor FC, Gottlieb AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2002;1(3):264-275.
44. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010; 11:180-210.
45. Papoutsaki M, Costanzo A, Mazzotta A, Gramiccia T, Soda R, Chimenti S. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154 (1):181-183. (Pubitemid 43381343)
46. Hawrot AC, Metry DW, Theos AJ, Levy ML. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol. 2006;23(1): 67-71.
47. Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21(1):87-88. (Pubitemid 38248978)
48. Paller AS, Siegfried EC, Langley RG, et al; Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241-251.
49. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233-240.
50. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007; 86(4):242-251. (Pubitemid 47067483)
51. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006;65(9):1233-1236. (Pubitemid 44277404)
52. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol. 2004;52(1):61-63. (Pubitemid 39077819)
53. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670-1677.
54. Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33(9):1802-1804. (Pubitemid 44373214)
55. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005;102(9):3372- 3377. (Pubitemid 40328052)
56. Pachman LM, Niewold T, Shrestha S, Morgan GA, Sullivan C. TNF-α levels and IFN-α activity in children with juvenile dermatomyositis ( JDM) are associated and modified by etanercept. Clin Immunol. 2009;131(suppl):S158.